Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.31M | -17.99M | -6.39M | 19.58M | 20.11M |
| Total Depreciation and Amortization | 2.12M | 2.10M | 1.96M | 1.74M | 1.52M |
| Total Amortization of Deferred Charges | 14.00K | 10.50K | 7.00K | 3.50K | -- |
| Total Other Non-Cash Items | 24.80M | 25.01M | 16.59M | -10.36M | -12.97M |
| Change in Net Operating Assets | -15.17M | -3.50M | -7.86M | -8.35M | -11.89M |
| Cash from Operations | 7.46M | 5.64M | 4.31M | 2.62M | -3.24M |
| Capital Expenditure | -1.63M | -1.27M | -1.68M | -1.59M | -809.60K |
| Sale of Property, Plant, and Equipment | 125.30K | 125.30K | 125.30K | 15.30K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -900.00K | -900.00K | -900.00K | -900.00K | -- |
| Cash from Investing | -2.40M | -2.05M | -2.46M | -2.47M | -809.60K |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 4.00M |
| Total Debt Repaid | -845.00K | -1.09M | -934.20K | -793.00K | -660.90K |
| Issuance of Common Stock | 19.30K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -825.70K | -1.09M | -934.20K | -793.00K | 3.34M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.23M | 2.50M | 922.50K | -646.60K | -705.50K |